Cargando…
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro
INTRODUCTION: Upregulation of PI3K/Akt/mTOR signalling in endocrine-resistant breast cancer (BC) has identified mTOR as an attractive target alongside anti-hormones to control resistance. RAD001 (everolimus/Afinitor®), an allosteric mTOR inhibitor, is proving valuable in this setting; however, some...
Autores principales: | Jordan, Nicola J, Dutkowski, Carol M, Barrow, Denise, Mottram, Huw J, Hutcheson, Iain R, Nicholson, Robert I, Guichard, Sylvie M, Gee, Julia MW |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978713/ https://www.ncbi.nlm.nih.gov/pubmed/24457069 http://dx.doi.org/10.1186/bcr3604 |
Ejemplares similares
-
The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
por: LI, SHAORU, et al.
Publicado: (2013) -
Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
por: Kauffman, Eric C., et al.
Publicado: (2019) -
mTORC2: The other mTOR in autophagy regulation
por: Ballesteros‐Álvarez, Josué, et al.
Publicado: (2021) -
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009) -
The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling
por: Delgoffe, Greg M., et al.
Publicado: (2011)